NASDAQ:INGN Inogen - INGN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Inogen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $22.78 +0.42 (+1.88%) (As of 01/26/2023 12:00 AM ET) Add Compare Share Share Today's Range$22.46▼$23.3050-Day Range$19.14▼$24.0652-Week Range$19.08▼$36.30Volume56,085 shsAverage Volume224,970 shsMarket Capitalization$522.14 millionP/E RatioN/ADividend YieldN/APrice Target$29.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Inogen MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside28.8% Upside$29.33 Price TargetShort InterestBearish5.11% of Float Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews Sentiment0.49Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.88) to ($1.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.92 out of 5 starsMedical Sector620th out of 1,048 stocksSurgical Appliances & Supplies Industry14th out of 23 stocks 3.2 Analyst's Opinion Consensus RatingInogen has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.33, Inogen has a forecasted upside of 28.8% from its current price of $22.78.Amount of Analyst CoverageInogen has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.11% of the float of Inogen has been sold short.Short Interest Ratio / Days to CoverInogen has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Inogen has recently increased by 2.70%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInogen does not currently pay a dividend.Dividend GrowthInogen does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInogen has received a 51.98% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Medical ventilators" product. See details.Environmental SustainabilityThe Environmental Impact score for Inogen is -1.12. Previous Next 1.9 News and Social Media Coverage News SentimentInogen has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Inogen this week, compared to 2 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inogen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.19% of the stock of Inogen is held by insiders.Percentage Held by Institutions95.93% of the stock of Inogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Inogen are expected to grow in the coming year, from ($1.88) to ($1.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inogen is -10.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inogen is -10.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInogen has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Inogen (NASDAQ:INGN) StockInogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.Read More Receive INGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inogen and its competitors with MarketBeat's FREE daily newsletter. Email Address INGN Stock News HeadlinesJanuary 23, 2023 | americanbankingnews.comInogen, Inc. (NASDAQ:INGN) Short Interest Up 15.4% in DecemberJanuary 17, 2023 | americanbankingnews.comInogen (NASDAQ:INGN) Stock Rating Lowered by William BlairJanuary 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 10, 2023 | finance.yahoo.comInogen Announces Preliminary Fourth Quarter and Full Year 2022 Revenue Within Company ExpectationsJanuary 10, 2023 | finance.yahoo.comInogen Achieves Regulatory Milestones to Support Current and Future ProductsDecember 27, 2022 | finance.yahoo.com3 Reasons to Retain Inogen (INGN) Stock in Your PortfolioDecember 13, 2022 | finance.yahoo.comInogen to Present at 41st Annual J.P. Morgan Healthcare ConferenceDecember 2, 2022 | seekingalpha.comInogen: No Change To Thesis, Similar Theme In Q3 NumbersJanuary 27, 2023 | UNKNOWN (Ad)Become an Investor in Brooklyn GinAward winning super-premium craft gin and upcoming Brooklyn distilleryNovember 4, 2022 | finance.yahoo.comInogen to Present at Upcoming Investor Conferences in November 2022November 3, 2022 | finance.yahoo.comInogen (INGN) Q3 Earnings and Revenues Beat EstimatesNovember 2, 2022 | finance.yahoo.comInogen Announces Third Quarter 2022 Financial ResultsNovember 2, 2022 | finance.yahoo.comInogen (INGN) Reports Q3 Loss, Tops Revenue EstimatesOctober 17, 2022 | nasdaq.com3 Reasons to Add Inogen (INGN) Stock to Your Portfolio Now - NasdaqOctober 14, 2022 | finance.yahoo.comIs There An Opportunity With Inogen, Inc.'s (NASDAQ:INGN) 43% Undervaluation?October 13, 2022 | finance.yahoo.comThe Global Smart Medical Devices Market to Exhibit Growth at a CAGR of 7.22% During the Forecast Period (2022–2027) | DelveInsight - Yahoo FinanceOctober 12, 2022 | nasdaq.com3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio - NasdaqOctober 5, 2022 | globenewswire.comPortable Oxygen Concentrators Market to Reach US$ 5.0 Bn by the year 2032 Owing to the Rise in Patients Suffering from Respiratory Diseases Globally | FMI - GlobeNewswireOctober 5, 2022 | businesswire.comInogen to Announce Third Quarter 2022 Financial Results on November 2, 2022 - Business WireOctober 5, 2022 | finance.yahoo.comInogen to Announce Third Quarter 2022 Financial Results on November 2, 2022September 29, 2022 | finance.yahoo.comEurope Energy Crisis Varied Impacts Across Countries - Yahoo FinanceSeptember 19, 2022 | finance.yahoo.comInogen Alliance Ranks in Environment Analyst's Top 100 Environmental & Sustainability Consultancy Firms 2022 Report - Yahoo FinanceSeptember 19, 2022 | globenewswire.comPortable Oxygen Kit Market Is Predicted to Reach USD 35.8 Billion by 2031, Says Allied Market Research - GlobeNewswireSeptember 17, 2022 | nasdaq.com3 Reasons to Hold Insulet (PODD) Stock in Your Portfolio - NasdaqSeptember 16, 2022 | finance.yahoo.comInogen (NASDAQ:INGN) Is In A Strong Position To Grow Its BusinessSeptember 14, 2022 | finance.yahoo.comAntea Group Ranked 14th in Environment Analyst's Top 100 Environmental & Sustainability Consultancy Firms 2022 Report - Yahoo FinanceSeptember 14, 2022 | finance.yahoo.comEkinops' SixSq and Kadiska deliver network performance monitoring from enterprise edge to cloud, web and SaaS applications - Yahoo FinanceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive INGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inogen and its competitors with MarketBeat's FREE daily newsletter. Email Address INGN Company Calendar Last Earnings11/02/2022Today1/26/2023Next Earnings (Confirmed)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INGN CUSIPN/A CIK1294133 Webwww.inogen.com Phone(805) 562-0500FaxN/AEmployees1,021Year FoundedN/APrice Target and Rating Average Stock Price Forecast$29.33 High Stock Price Forecast$36.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+28.8%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,330,000.00 Net Margins-13.69% Pretax Margin-9.22% Return on Equity-11.02% Return on Assets-8.31% Debt Debt-to-Equity RatioN/A Current Ratio4.83 Quick Ratio4.29 Sales & Book Value Annual Sales$358 million Price / Sales1.46 Cash Flow$0.65 per share Price / Cash Flow34.91 Book Value$16.29 per share Price / Book1.40Miscellaneous Outstanding Shares22,921,000Free Float22,648,000Market Cap$522.14 million OptionableOptionable Beta0.93 Key ExecutivesMr. Nabil Shabshab (Age 58)CEO, Pres & Director Comp: $3.24MMr. Bart Sanford (Age 57)Exec. VP of Operations Comp: $558.22kDr. Stanislav Glezer M.D. (Age 50)MBA, Exec. VP & CTO Comp: $628.3kMr. George J. Parr (Age 52)Exec. VP & Chief Commercial Officer Comp: $799.95kMs. Kristin A. Caltrider (Age 55)Exec. VP, CFO & Treasurer Ms. Agnes LeeSr. VP of Investor Relations & Strategic PlanningMr. Jason Somer (Age 55)Exec. VP, Gen. Counsel & Corp. Sec. Ms. Jennifer Yi BoyerExec. VP & Chief HR OfficerMr. Matthew PigeonInvestor Relations OfficerMore ExecutivesKey CompetitorsSanara MedTechNASDAQ:SMTIVicarious SurgicalNYSE:RBOTAvanos MedicalNYSE:AVNSEstablishment LabsNASDAQ:ESTAArtivionNYSE:AORTView All CompetitorsInsiders & InstitutionsStrs OhioSold 9,600 shares on 1/26/2023Ownership: 0.043%Investment Management of Virginia LLCSold 7,678 shares on 1/23/2023Ownership: 0.122%Assenagon Asset Management S.A.Bought 44,576 shares on 1/12/2023Ownership: 0.308%Yousif Capital Management LLCSold 3,935 shares on 1/9/2023Ownership: 0.064%Bank of New York Mellon CorpBought 14,778 shares on 12/8/2022Ownership: 0.899%View All Insider TransactionsView All Institutional Transactions INGN Stock - Frequently Asked Questions Should I buy or sell Inogen stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" INGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares. View INGN analyst ratings or view top-rated stocks. What is Inogen's stock price forecast for 2023? 3 Wall Street analysts have issued 12-month price targets for Inogen's shares. Their INGN share price forecasts range from $22.00 to $36.00. On average, they anticipate the company's share price to reach $29.33 in the next twelve months. This suggests a possible upside of 28.8% from the stock's current price. View analysts price targets for INGN or view top-rated stocks among Wall Street analysts. How have INGN shares performed in 2023? Inogen's stock was trading at $19.71 at the beginning of 2023. Since then, INGN stock has increased by 15.6% and is now trading at $22.78. View the best growth stocks for 2023 here. When is Inogen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our INGN earnings forecast. How can I listen to Inogen's earnings call? Inogen will be holding an earnings conference call on Thursday, February 23rd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13735129". How were Inogen's earnings last quarter? Inogen, Inc. (NASDAQ:INGN) posted its quarterly earnings results on Wednesday, November, 2nd. The medical technology company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.23. The medical technology company earned $105.39 million during the quarter, compared to analyst estimates of $97.57 million. Inogen had a negative trailing twelve-month return on equity of 11.02% and a negative net margin of 13.69%. What guidance has Inogen issued on next quarter's earnings? Inogen issued an update on its fourth quarter 2022 earnings guidance on Tuesday, January, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $87.50 million-$88.50 million, compared to the consensus revenue estimate of $89.55 million. What is Scott Wilkinson's approval rating as Inogen's CEO? 70 employees have rated Inogen Chief Executive Officer Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among the company's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Inogen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX). What is Inogen's stock symbol? Inogen trades on the NASDAQ under the ticker symbol "INGN." Who are Inogen's major shareholders? Inogen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.31%), Investment Management of Virginia LLC (0.12%), Yousif Capital Management LLC (0.06%), Comerica Bank (0.06%) and Strs Ohio (0.04%). Insiders that own company stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Holdings A/S Novo, Ray Benjamin M Anderson and Raymond Huggenberger. View institutional ownership trends. How do I buy shares of Inogen? Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Inogen's stock price today? One share of INGN stock can currently be purchased for approximately $22.78. How much money does Inogen make? Inogen (NASDAQ:INGN) has a market capitalization of $522.14 million and generates $358 million in revenue each year. The medical technology company earns $-6,330,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis. How many employees does Inogen have? The company employs 1,021 workers across the globe. How can I contact Inogen? Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The official website for the company is www.inogen.com. The medical technology company can be reached via phone at (805) 562-0500 or via email at mpigeon@inogen.net. This page (NASDAQ:INGN) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.